EU research is optimising the delivery of healthcare to European citizens and increasing the competitiveness of the medical and pharmaceutical industries.
EU funding in 2008
"EU initiatives are generating the critical mass to combat global health threats."
The importance the EU attaches to medical research is reflected in the €6 billion budget assigned to the sector under the Seventh Framework Programme, with the goal of translating basic research into real healthcare benefits and increasing the quality of life.
Community funding of multinational consortia and the coordination of national funding bring down barriers between countries, through programmes such as the Europe-Developing Countries Clinical Trials Partnership (EDCTP), which concentrates Member States’ efforts on fighting global health threats such as HIV/AIDS, malaria and tuberculosis.
The critical mass of action possible at EU level fosters cooperation between all actors: universities, research centres, hospitals, SMEs, large companies, foundations and patients' organisations. A focus on translating basic discoveries into clinical applications also promotes exchanges between scientific disciplines, bringing together researchers, engineers, clinicians and industrialists.